Status:
COMPLETED
Analysis of New Salivary Biomarkers to Evaluate Excessive Diurnal Sleepiness in Children With Hypersomnia
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Hypersomnia
Sleepiness, Excessive Daytime
Eligibility:
All Genders
6-18 years
Brief Summary
Excessive diurnal sleepiness is characterized by an incapacity to stay awake, in favour of sleep occurrence. This sleepiness might be secondary to a sleep disorder; when it is not the case, it is prim...
Eligibility Criteria
Inclusion
- Children with excessive diurnal sleepiness hospitalized for an evaluation of hypersomnia symptoms
- Age\> 6 years old and \<18 years old
- Non opposition by both parents
Exclusion
- Opposition of the child or parents to participate
- Patients under measure of deprivation of rights and liberty
Key Trial Info
Start Date :
April 11 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 20 2024
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT05183464
Start Date
April 11 2022
End Date
November 20 2024
Last Update
February 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Mère-Enfant - Service d'épileptologie clinique, des troubles du sommeil et de neurologie fonctionnelle de l'enfant
Bron, France, 69677